Ovarian Cancer

In this episode of the “CURE Talks Cancer” podcast, we spoke with a gynecologic cancer expert about how her sister’s journey with ovarian cancer provided her with a different perspective that would lead to raising awareness for others.

Two evaluations for treatment responses in women with ovarian, fallopian tube or primary peritoneal carcinoma may need to take into consideration other factors such as other existing conditions.

A cancer survivor remembers his wife who died of complications from ovarian cancer on Valentine’s Day several years ago. His advice to everyone: Holidays gradually become positive reflections of all that was good before cancer took it away.

Diane Powis spent more than 10 months bouncing from one doctor to the next before finally being “blindsided by” a diagnosis of stage 3 ovarian cancer. But as her initial feelings of isolation and fear wore off, Powis soon learned that she wasn’t alone – and that help and information were out there.

At the moment it may be hard to realize, but your life is not over because of cancer.

In this episode of the “CURE® Talks Cancer” podcast, we spoke with a patient who was blindsided by her stage 3 ovarian cancer diagnosis several years ago. We talk about how she spent months going from specialist to specialist before finally receiving her diagnosis, and why she dedicates much of her time to advocating for others.

Women who reported using oral contraceptives had a decreased risk of endometrial and ovarian cancer, compared to those who never used the hormone medications. The data also indicated the association extended up to three decades after patients stopped using the contraceptives.

It’s okay for me to not feel like celebrating my 5-year cancerversary in a world that is upside down and backward because of COVID-19. Yes, I’m grateful and blessed, but I’m not bullet-proof. I’m human. I don’t have to feel guilty. None of us do.

In an interview with CURE®, the “Felicity” and “Scandal” actor spoke about his experience as a caregiver to his mother, and why women should not just watch and wait for their ovarian cancer to recur.

A gynecologic oncology expert from the University of California, Davis reviewed early-stage ovarian cancer and the importance of knowing what options are available before, during and after treatment.

A roundup of some ovarian cancer news and updates that occurred in 2020 that patients may have missed.

Women with ovarian cancer report a better quality of life when treated with a combination of Keytruda, Avastin and oral metronomic cyclophosphamide.

Keytruda (pembrolizumab), Avastin (bevacizumab) and cyclophosphamide contributed to a clinical benefit in 95% of women in the trial and a durable treatment response of 12 months or longer in 25% of women.

Watch the entire Ovarian Cancer Heroes program right here!

An oncology nurse, patient turned advocate and cancer biologist were honored during CURE®’s third annual Ovarian Cancer Heroes program where they got to share messages of resiliency with a virtual audience.

Time is a valuable commodity, especially for patients with cancer who may find themselves with limited time or limited free time to enjoy the things they loved prior to their cancer. But the COVID-19 pandemic is robbing patients of that precious time.

Five-year follow-up data from the phase 3 SOLO-1 trial demonstrates a nearly five-year delay in disease progression with Lynparza compared with a delay of just over a year with placebo in women with newly diagnosed, advanced ovarian cancer harboring a BRCA gene mutation.

A weekly high dose of chemotherapy did not improve survival for patients with epithelial ovarian cancer, though the treatment regimen was effective and well-tolerated.

A proposed preventive surgery that would take out fallopian tubes before menopause but save ovary removal until afterwards was favored by most premenopausal previvors of ovarian cancer in a study.

The study results also showed that older age was significantly associated with lower cancer genetics knowledge, which, according to a post-doctoral research fellow at Dana-Farber Cancer Institute, is important because older adults may serve as a resource for family members who seek information about their family's health history.

Compared to physician’s choice of chemotherapy, the MEK inhibitor Mektovi failed to improve progression-free survival in patients with low-grade serous ovarian carcinomas. However, the study authors note Mektovi demonstrated promising results that support continued use of the treatment.

The National Ovarian Cancer Coalition to host its annual "Together in Teal®" No Boundaries National Broadcast Celebration During September awareness month on Saturday, Septemeber 26, 2020.

Immediate treatment with Lynparza after standard surgery and chemotherapy should be considered for all patients with newly diagnosed stage 3 or 4 ovarian cancer that carries a BRCA gene mutation, even if residual disease remains, researchers have found.

Nearly half (48%) of the patients reported experiencing significant fatigue following their surgery. Thirty-nine percent of the patients still reported significant fatigue one year following their surgery.

Here is a list of the recent trial initiations that occurred within the cancer space in August.